Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Nektar Therapeutics

+ Add to Watchlist

ITH:GR

9.935 EUR 0.103 1.05%

As of 13:40:27 ET on 03/27/2015.

Snapshot for Nektar Therapeutics (ITH)

Open: 9.909 Day's Range: 9.906 - 10.150 Volume: 70
Previous Close: 9.832 52wk Range: 7.500 - 13.636 1-Yr Rtn: +11.49%

Stock Chart for ITH

No chart data available.
  • ITH:GR 9.906
  • 1D
  • 1M
  • 1Y
9.832
Interactive ITH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ITH

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.4100
Est. PEG Ratio -
Market Cap (M EUR) 1,305.28
Shares Outstanding (M) 131.38
30 Day Average Volume 303
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ITH

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ITH

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.

Howard W RobinPresident/CEOJohn L NicholsonSenior VP/CFO
Stephen K DobersteinSenior VP/Chief Scientific OfcrGil M LabrucherieSenior VP/Secy/Gen Counsel
More Company Profile & Key Executives for ITH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil